radiopharmaceuticals News & Analysis

Lantheus (LNTH) Set for $8 Billion Acquisition by Curium

Curium has agreed to acquire Lantheus Holdings (LNTH) for up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash at closing, plus potential additional payments of up to $12 per share contingent on future sales targets by 2030. This results in a total potential consideration of $114.50 per share, which is a premium of approximately 14.9% over Lantheus' last closing price of $99.64. This acquisition is significant as it reflects a validation of Lantheus' decades-long innovation in the radiopharmaceutical sector, impacting stakeholders and investors in the field.